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Title: Lived experiences and support needs of women who developed chemotherapy-
induced peripheral neuropathy following treatment for breast and ovarian cancer  
 
Abstract  
This study explored lived experiences of women who developed chemotherapy-
induced peripheral neuropathy (CIPN) following treatment for breast and ovarian 
cancer. It also explored cancer survivors’ perceptions of information and advice offered 
by clinicians about CIPN and for managing CIPN. The study was advertised through 
cancer charity websites and social media accounts. Purposeful, convenience sampling 
was carried out using set eligibility criteria. Individuals with diagnosis of breast or 
ovarian cancer who experienced or are still experiencing CIPN were recruited.  Fifteen 
semi-structured interviews were conducted. Data were analysed using interpretative 
phenomenological analysis (IPA). Similar to previous studies, participants used 
comparisons to describe their symptoms. Four main themes emerged from the analysis: 
(1) struggle to process CIPN information, (2) information and trust are key in the 
treatment decision-making process, (3) experience of symptom-reporting and (4) 
challenges of managing symptoms. Findings suggest interventions to improve 
understanding of CIPN risk are needed in practice. A better and broader understanding 
of the patient experience of CIPN could pave the way for improved communication, 
assessment and management of symptoms. Results suggest the need for interventions 
to guide cancer survivors to recognise and report CIPN symptoms early and address the 
impact of CIPN symptoms in their lives.  
 
Keywords:  chemotherapy-induced peripheral neuropathy, chemotherapy, patient 
experience, cancer, survivorship, phenomenology 
 
 
 
 
 
 
 
 
 
  
Introduction  
 
There is clear evidence that symptoms of chemotherapy-induced peripheral neuropathy 
can affect an individual long after treatment has finished (Hershman et al. 2014). 
Chemotherapy-induced peripheral neuropathy (CIPN) is an umbrella term used to 
denote nerve damage caused by neurotoxic chemotherapy drugs (Park et al. 2013 
Miltenburg & Boogerd 2014). An example is Paclitaxel, a neurotoxic drug, used as 
first-line chemotherapy treatment for ovarian cancer which may be combined with 
platinum-based compound that also has neurotoxic effects (NICE, 2015). Symptoms of 
CIPN are mainly characterised by numbness and tingling of the hands and feet, but also 
include other symptoms such as pain, muscle weakness and sensitivity to cold 
(Tofthagen et al. 2012). The onset, nature, duration and severity of symptoms depends 
on the drug and cumulative dose (Argyriou et al. 2012).  To date, evidence-based 
treatment for CIPN is lacking while prevention is limited to dose reduction, delay or 
discontinuation of treatment (Hershman et al. 2014).  
 
CIPN is known to negatively affect the quality of life of those who develop it (Mols et 
al. 2014, Tanay et al. 2016). Individuals become more prone to falls and injury 
(Tofthagen et al. 2012, Mohile 2013, Gewandter et al. 2014). Carrying out activities 
which involve the hands and feet, such as driving, typing on computers, writing, 
sewing, painting and handling tools, become difficult or challenging (Tanay et al. 
2016). Patients and their caregivers report financial losses as a result of having to reduce 
their working hours or having to give up their job due to dexterity problems. Studies in 
the United States (US) show patient and carer work loss amounted to $4,220 per patient 
over a nine-month period (Calhoun et al. 2001). There is also a potential economic 
impact to the health service. A study by Pike et al. (2012) in the US showed that 
healthcare providers spend up to $17,344 more if patients develop CIPN, due to extra 
outpatient drugs and devices, more outpatient visits and hospitalisations (Calhoun et al. 
2001).  
 
In the United Kingdom (UK), previous nationwide patient satisfaction surveys show 
CIPN is a persistent problem for cancer survivors. Free-text responses from a survey 
conducted by the Department of Health in England suggest there is inadequate 
preparation about the extent to which CIPN could affect them and insufficient advice 
  
is provided on its management (Corner and Wagland 2012).  As survival rates for many 
types of cancer increase and improve (Cancer Research UK 2015), providing 
information about potential side effects of treatment and access to advice about 
symptom management is paramount to promote recovery, health and wellbeing after 
treatment (NCSI 2013). Despite its negative effect on cancer survivors’ quality of life 
long after treatment is completed and substantial personal and healthcare costs, patient 
perception of CIPN risk are not prominent in the cancer experience and only surface 
when symptoms are severe (Tanay et al. 2016). It is also unclear from the literature 
what influences patients’ perception of CIPN risk and current clinical management 
from patients’ views. It is vital that research is conducted to gain better understanding 
of current clinical management of CIPN as perceived by patients. Consequently this 
study aimed to address the lack of research exploring the lived experience of CIPN of 
people with cancer survivors in the UK (Tanay et al. 2016).   
 
Aim 
This study aimed to explore lived experiences of UK cancer survivors living with 
symptoms of CIPN following treatment of breast and ovarian cancer. It also explored 
cancer survivors’ perceptions of information and advice offered by clinicians about 
CIPN and for managing CIPN symptoms.  
 
 
Methods 
 
A phenomenological approach was employed to understand real life experiences of 
individuals who had or still have symptoms of CIPN and to investigate the meaning of 
their experiences (Green and Thorogood 2018). The study was advertised once through 
cancer charity websites and social media accounts e.g. WordpressTM, TwitterTM and 
FacebookTM with permission obtained from charity gatekeepers. Purposeful, 
convenience sampling was employed and participants recruited if they met the study 
eligibility criteria (Table 1). The study information sheet and researcher’s contact 
details were provided by either email or post to those who expressed a willingness to 
participate. We aimed to recruit up to 20 participants from across the United Kingdom. 
A total of 54 individuals responded within the first two weeks of recruitment and were 
all sent patient information sheets. Eighteen (n=18) of 34 individuals who responded 
  
after being sent a patient information sheet agreed to participate and signed a consent 
form. Two were subsequently found to be ineligible and one participant was not 
interviewed for health reasons. Fifteen semi-structured audio recorded telephone 
interviews were conducted by the primary author (MT) at a time convenient to the 
participants between September 2015 and June 2016. Open-ended questions were used 
to explore their experiences (Patton 2002). For example, ‘How was neuropathy 
explained to you?’; ‘Describe how neuropathy affected your daily life and activities’; 
‘Describe how the information you received helped you to recognise the symptoms’; 
‘What support was provided to help you address the symptoms?’. These questions 
provided an opportunity to further explore participants’ experiences (Patton 2002). 
Interviews lasted 20-54 minutes. 
 
Data were analysed using interpretative phenomenological analysis (IPA) to explore 
how individuals made sense of their experiences (Smith and Osborn 2003). This 
approach allowed exploration of the participants’ perspectives of their experience 
while permitting the researchers to conceptualise and interpret an individual’s world 
(Smith et al. 2009). The interviews were transcribed verbatim. After repeated reading 
of the entire transcripts, preliminary themes were identified. Themes were grouped 
and clustered and main themes were organised across transcripts (Smith and Osborn 
2003). Emerging key themes represented the nature of participants’ experiences 
(Willig & Stainton Rodgers 2008). Both researchers (MT, JA) participated in the 
analysis process and confirmed the themes. Data were managed using Microsoft 
Excel© software. The study was approved by King’s College London, Psychiatry, 
Nursing and Midwifery Research Ethics Subcommittee (HR-14/15-1759). 
 
 
Results  
 
Of fifteen female participants (n=15) recruited to the study, thirteen (n=13) were 
diagnosed with ovarian cancer. One participant was diagnosed with breast cancer and 
one was diagnosed with peritoneal cancer but was included because her initial diagnosis 
was ovarian cancer. The mean age was 62 years (range 50-76 years), and all participants 
described themselves as White-British or White-European ethnicity. At the point of 
data collection, the average time since participants completed chemotherapy treatment 
  
was 4.4 years (range 0.5-18 years). Although all participants were still experiencing 
CIPN symptoms, intensity varied from mild to severe. Participants resided and received 
chemotherapy treatment across different regions of the UK; about 40% were treated in 
London. Table 2 shows participants’ demographic profile and chemotherapy drugs they 
received. Data regarding modifications in chemotherapy schedules were not collected. 
 
Four main themes emerged from the analysis: (1) struggle to process CIPN information, 
(2) information from and trust in clinicians are key, (3) experience of reporting CIPN 
symptoms and (4) challenge of managing CIPN symptoms. Table 3 provides examples 
of quotes illustrating the main themes and sub-themes while Figure 1 presents a 
thematic diagram of the four main themes.  
 
 
Theme 1: Struggle to process CIPN information 
 
Overwhelming information before starting treatment 
Participants reported that information about CIPN was sandwiched between layers of 
information about cancer and chemotherapy which they received prior to starting 
treatment. They mentioned being given ‘a whole list of side-effects’ (P-02, P-08, P-12, 
P-13, P-14) and having ‘a big discussion about the treatment’ (P-01). For them, there 
was so much information that it was very hard to absorb everything that was said, 
especially so close to being diagnosed with cancer (P-06, P-08). Despite feeling 
bombarded by too much information, decisions had to be made quickly (P-01, P-03, P-
06). They felt they were being ‘swept along with what clinicians were saying’ (P-03) 
despite having difficulty understanding everything that was said about the treatments.  
 
Little or no information about CIPN 
Most participants mentioned that they did not get any information, did not remember 
getting information (P-01, P-06, P-15) or only received minimal information about 
CIPN (P-02, P-04, P05, P-12, P-14). They reported that although CIPN was listed on 
the written chemotherapy information, clinicians did not put enough emphasis on how 
CIPN could affect their quality of life (QOL) leaving them surprised when symptoms 
appeared and lingered for a long time (P-03, P-06).  
 
  
Potential risk is uncertain  
Participants mentioned that information about the potential risk of CIPN and potential 
severity of CIPN symptoms lacked clarity. Prior to chemotherapy, they were told that 
it ‘may not affect them’ (P-04, P-013). One was told ‘not to get too paranoid about the 
side-effects’ and felt ‘the nurse was protecting her from becoming too anxious’ (P-13). 
Another participant said ‘they [clinicians] don't want to talk about the side effects   
because they know that lots of people probably would query a lot more and possibly 
wouldn't go ahead with the chemo’ (P-04). When CIPN symptoms started to appear and 
the duration of CIPN symptoms were discussed, some participants were told it ‘will 
probably clear up’, ‘may get better’, or ‘should not last for much beyond the end of 
treatment’ – participants said they did not find such comments useful or helpful (P-01, 
P-03, P-08, P-09). While many participants mentioned that their symptoms improved 
over time, all were still experiencing residual CIPN symptoms at the time of data 
collection. For some, symptoms were still severe and significantly diminished their 
QOL even after months or years from completion of treatment.  
 
 
Theme 2: Information and trust are key 
 
Those who reported receiving adequate information felt empowered as they knew what 
symptoms to look out for. They said that information helped manage their anxieties – 
‘I think that (information) is really important because you don’t get anxious’ (P-08, P-
09, P-10). One pointed out that having detailed information about CIPN had not 
deterred her from having chemotherapy (P-10). When decisions had to be made about 
treatment due to CIPN symptoms, those who received information trusted their 
clinicians and felt included in the treatment decision-making process (P-05, P-10, P-12, 
P-13). While participants acknowledged that ‘not having chemotherapy’ was not a 
decision they would have made at the time, specific and ongoing information about 
CIPN would have better prepared them for its deleterious effect on their lives (P-01, P-
03, P-09, P-10, P-12, P-15).  
 
 
Theme 3: Experience of symptom-reporting 
 
  
Reported but not followed-up 
It was unclear to participants when assessment of CIPN symptoms should happen. 
Some were told that they must report CIPN symptoms as soon as possible, but those 
who did this were not followed-up by a clinician for a few weeks (P-09, P-11). Some 
were given further chemotherapy cycles without CIPN reassessment or discussion 
taking place; during which time their symptoms worsened (P-04, P-11). Participants 
who were enrolled in clinical trials and hence had regular follow-up with clinicians felt 
CIPN symptoms they reported were only collected for the trial purposes as nothing was 
done to help alleviate them (P-04, P-06). Similarly, participants seen by chemotherapy 
nurses prior to each chemotherapy cycle were asked about their CIPN symptoms but 
no further contact was made after ’data was collected’ (P-10, P-03). 
 
 
Felt ignored 
Some participants felt they ‘were not listened to’, ‘dismissed’ (P-04) and ‘ignored’ 
when they mentioned their CIPN symptoms (P-03, P-06-P-14); and as a result they 
learned not to report them (P-01, P-02, P-03). The impression they got was that they 
were ‘misunderstood’ by clinicians and ‘nobody was taking their symptoms seriously’ 
(P-03, P-15). There were several explanations participants suggested as reasons for 
clinicians’ not taking notice of their CIPN symptoms. These included: clinicians are 
‘too busy’ (P-15), a notion that ‘CIPN is so common and didn’t surprise anybody’ (P-
03, P-06, P-14), clinicians say ‘symptoms are temporary’ (P-03, P-08, P-09) and that 
they only take notice when patients ‘cannot cope with the symptoms anymore’ (P-10, 
P-11). A participant suggested that there should be ‘more acknowledgment that CIPN 
affects many people, because it is a bit of a secret thing’ (P-14) and that ‘clinicians 
should listen more to their patients’ (P-04). Having experienced how CIPN negatively 
affected their lives, participants, with hindsight, wished they had ‘insisted for clinicians 
to take more notice’ (P-03, P-04) rather than ‘not making a fuss’ despite ‘suffering the 
symptoms’ (P-01).  
 
 
Theme 4: Challenge of managing symptoms 
 
  
Participants used metaphors to describe their symptoms, as highlighted in earlier 
qualitative studies (Tanay et al. 2016). Examples are: ‘walking on fine gravel or sand’, 
‘was like walking on needles’, ‘walking on marbles or pebbles’, ‘scrunched-up socks 
under my foot’, ‘feeling like nails coming off the nailbed’, ‘getting an electric shock’, 
‘like wearing strange gloves’ and ‘like having an anthill on my feet’. CIPN had a 
profound disabling effect on their daily lives and everyday life became fraught with 
danger, even in their own homes. 
 
‘Difficult to write, really difficult to hold a pen and control that, quite difficult 
to type on a computer. I’d drop things quite a lot’ (P-09). 
 
‘I ended up breaking a rather precious and expensive casserole because I, I 
didn’t get the hold of it properly’ (P-10). 
  
‘I look at my lovely shoes sitting in the wardrobe that I can't wear any more’ 
(P-03) 
 
Participants mentioned how CIPN symptoms restricted their movement, sometimes 
keeping them from going out of their homes. This was highlighted as a significant effect 
on their quality of life as they were unable to socialise, made worse by fear of falling 
and injury.   
 
‘I couldn’t manage to do a length of a walk anywhere’ (P-05) 
 
‘I stopped going into my office and I had to pretty much stay put and work from 
my armchair. It also definitely affected my moving around the house. It’s not as 
insignificant as people think perhaps’ (P-06). 
 
‘Sometimes my legs go numb and sometimes it starts when I’m walking, which 
means I have to stop because I can’t feel the leg and I can fall.  I want to say 
the quality of life has been severely affected. I have to think very hard before I 
go anywhere’ (P-15). 
 
 
  
Dealing with symptoms with minimal clinician input  
Most participants felt they were left to manage their symptoms on their own and were 
unsure where to seek help about CIPN symptoms, particularly after discharge (P-04, P-
07, P-13). They felt clinicians were dismissive of their symptoms and that their attitude 
suggests that CIPN is a price worth paying to survive cancer, and is viewed as ‘an 
acceptable and expected symptom’ (P-02, P-04, P-06, P-09, P-10, P-12). Further, some 
participants suggested that people who have not experienced CIPN will find it difficult 
to understand – this is why ‘clinicians cannot relate to it all and so it [CIPN] is put on 
the backburner’ (P-04, P-09, P-14, P-15). Some mentioned that maybe ‘they 
[clinicians] do not have the information on what to do or there is nothing to tell’ (P-
03, P-04). Many participants no longer reported their CIPN symptoms as they were left 
to ‘get on with it’ or ‘put up with it’ (P-01, P-02, P-04-06), and ‘would not want to 
trouble the doctor’ (P-01, P-02). 
 
Lack of practical advice on self-management 
Participants overwhelmingly suggested ‘more practical advice to support self-
management of CIPN symptoms’ was needed (P-01, P-02, P-05, P-09-11, P13-15). 
They felt clinicians focused on managing their symptoms using pharmacological 
approaches, mainly to manage the pain, until they ran out of drugs to prescribe (P-01, 
P-11). However, participants pointed out the usefulness of information about self-
management approaches that could help minimise the severity of their symptoms, 
mitigate the effects of CIPN and possibly help them get back to doing the things that 
they enjoyed doing (P-04, P-07 and P-13). Many obtained self-management 
information from other cancer survivors rather than from members of the chemotherapy 
team. These include using hot or cold packs, wearing walking boots, choosing clothes 
that have no buttons, performing video calls rather than telephone calls, bringing poles 
when walking and wearing sufficient warm clothing during cold weather. Many 
participants mentioned how acupuncture, reflexology and massage also minimised 
symptoms.  
 
Searching for elusive information  
Various avenues were accessed by participants to obtain more information about CIPN 
such as on-line discussion groups and websites with CIPN content. The majority 
accessed a variety of cancer charity websites both in the UK and USA, as well as 
  
medical sites including information about diabetic neuropathy. What participants found 
most useful were patient forums where cancer survivors shared their individual CIPN 
experiences and interventions they used to minimise symptoms. On the other hand, 
participants expressed frustration about there not being a single place available to obtain 
information about CIPN and the fact that they had to find the information themselves. 
Many compared some of their issues to those experienced by individuals with diabetic 
neuropathy but felt disappointed that neuropathy services for cancer survivors are not 
well established.  
 
Interpretative analysis of our findings suggests that CIPN was not experienced as the 
minor or discrete symptom described by clinicians. Rather participants saw themselves 
as profoundly disabled and socially isolated as CIPN impacted every aspect of their day 
to day lives.  Moreover many described how they suffered in silence because clinicians 
appeared to ignore or dismiss their reports of CIPN symptoms and so they were forced 
to seek alternative sources of information and support. This implies that clinicians lack 
understanding of the wide ranging and negative impact that CIPN can make on the 
quality of life of people treated for cancer. They seem blind to the notion that whilst the 
treatment has successfully eliminated the cancer, it has permanently disabled the 
person. This suggests the consequences of CIPN are ‘hidden’ from view and are 
shouldered in private by those who suffer from them. 
 
 
Discussion  
 
Our findings highlight the negative impact of CIPN on those who experience them, 
which is consistent with previous studies (Boehmke & Dickerson 2005; Bakitas 2007; 
Tofthagen 2010b; Speck et al. 2012),. Functional limitations because of symptoms 
involving their hands and feet resulted in challenges performing household and work 
activities. Recent studies showed CIPN was associated with falls and injuries (Winters-
Stone et al. 2017). Participants in our study described that they felt unsafe and worried 
that they may fall, with some who reported they had fallen because of CIPN symptoms. 
These effects compromise cancer survivors’ road to recovery. Lack of confidence and 
fear of falling may prevent an individual from doing their usual activities at home.  Falls 
and injuries could prolong inactivity, delay resumption of daily activities and 
  
performance of social roles and can also delay return to work which can have economic 
implications. As previous cost analysis studies showed, CIPN also has financial 
implications for the health service as symptoms and lead to functional consequences of 
CIPN that may require additional pharmacological treatment and medical devices, extra 
outpatient appointments and longer hospital stays (Pike et al. 2012, Calhoun et al. 2001)  
 
As severity of CIPN symptoms are dose-related, it is paramount that healthcare 
professionals and patients work together to restrict progression of symptoms by 
delaying or reducing treatment (Park et al. 2013). Clear information about CIPN will 
help patients recognise CIPN symptoms early. Evidence suggests that when individuals 
understand the benefits and risks of their treatment, they become more involved in their 
care (Ahmed 2012). If CIPN symptoms are recognised early, these can be reported as 
soon as possible so individuals can be offered appropriate support by their clinicians.  
However, despite the potential considerable impact on patient’s quality of life, our 
findings showed that patients felt little or no information about CIPN risk was provided 
to them prior to start of treatment - similar to findings from previous research wherein 
participants felt inadequately informed about CIPN (Boehmke & Dickerson 2005; 
Bakitas 2007; Tofthagen 2010a).  
 
The women in our study reported feeling overwhelmed when provided with large 
amounts of information about their treatment and potential side effects so close after 
the time of cancer diagnosis (Corner and Bailey 2009). This may explain their poor 
grasp or incomplete processing of important information. It was also clear that 
participants struggled to understand the relevance of CIPN risk at the start of treatment, 
and that when they reported CIPN symptoms to clinicians, the uncertainty of CIPN 
became magnified. Edwards et al. (2002) suggest using graphics to offer a visual 
representation to facilitate understanding and comparison of risks. Using easy-to-
understand graphs can help explain incidence and duration of CIPN symptoms to 
patients. For example, Ozanne et al. (2014) developed a tool that provides risk 
assessment and decision support for both patients and clinicians to use collaboratively. 
Participants in our study felt their clinicians withheld some information to protect them 
from worrying or feeling anxious about their treatment. However, they (participants) 
suggested that they would have wanted more information about the risk of CIPN and 
how it may affect them.  Participants also suggested that receiving clear information 
  
from clinicians helped to develop trust, enhancing confidence in their clinicians 
especially when making difficult treatment decisions such as dose-reduction, delaying 
or discontinuing treatment. Previous research shows that trust and emotions affect 
individual perceptions and decisions about risks (Slovic et al. 2004) and may help to 
empower patients to involve themselves in decision-making. But it is unclear from our 
findings what CIPN information is adequate or too much for patients. Further research 
is needed to explore patients’ perceptions about the amount and content of information, 
when CIPN information is needed and how CIPN information is best delivered to 
emphasise the risks. Strategies such as appropriate timing, gradual and continued 
reinforcement of information, particularly late onset or long-term side-effects of 
chemotherapy such as CIPN, may help patients to effectively process information.  
 
The challenge of CIPN assessment does not lie solely on the lack of patient’s 
recognition of symptoms.  As highlighted in earlier American studies (Tanay et al. 
2016), women in this study felt ignored when they reported CIPN symptoms to 
clinicians and highlighted a lack of further or proactive assessment of CIPN symptoms 
by nurses and doctors. This may be due to a lack of consensus as to the most appropriate 
assessment tool for CIPN (Curcio 2016) and because treatments options are limited 
(Arygyriou et al. 2012), possibly making CIPN difficult to discuss if clinicians cannot 
offer other interventions. Further, assessments such as nerve conduction studies, 
Rydel-Seiffer tuning fork and 10 g monofilament (Cavaletti et al. 2012) are time-
consuming to conduct and require specialist skills. There is also evidence in our study 
that the potential severity and impact of CIPN symptoms were somewhat downplayed 
by clinicians. Clinicians’ attitudes that leant towards the temporary nature of CIPN 
symptoms rather than long-term, coupled with ignoring behaviour when patients report 
their symptoms, may prevent early CIPN management. Patients can become 
discouraged and disinterested in reporting CIPN symptoms if their symptoms are 
ignored or downplayed.  
 
Findings in our study strongly indicate that participants wanted more information about 
how they could better cope with CIPN on a day to day basis. Mirroring findings from 
previous studies (Tanay et al. 2016), participants in our study described CIPN 
symptoms using metaphors and analogies. This may be their way of emphasising that 
CIPN is a different experience, not merely ‘pins and needles’, a term commonly used 
  
to explain the symptoms.  They highlighted that the experience of CIPN will be difficult 
to understand for those who have not experienced the symptoms. Thus, research studies 
using questionnaires with limited choices to describe neuropathy symptoms should also 
allow patients to describe their symptoms in their own words. During clinical 
assessment, individuals should also be encouraged to describe their CIPN symptoms 
and explain how these affect their daily activities.  
 
CIPN affects various aspects of daily living such as work, social, leisure and domestic 
activities (Tanay et al. 2016). The women in our study mentioned how CIPN symptoms 
affected their lives resulting to social isolation, safety issues and difficulties in 
performing tasks at home and at work.  Information about social/family roles, 
occupation, lifestyle and activities during patient-clinician dialogue may be necessary, 
taking into account the realities of how CIPN affects patients and cancer survivors in 
their daily lives. Without guidance, coping with functional consequences of CIPN 
symptoms can be challenging for individuals as they try to minimise the impact on their 
lives.  
 
Most participants obtained CIPN information from other sources. As a result of 
receiving information from clinicians, a small number of participants felt empowered.  
This supports findings from a study by Yates et al. (2005) in which an educational 
intervention showed potential to empower women to cope with cancer fatigue. 
Participants also highlighted the usefulness of practical suggestions from other cancer 
survivors which they accessed through charity events, health forums and chatrooms. 
There is evidence to suggest that group education improves patients’ knowledge about 
their specific illness and self-care (Steinsbekk et al. 2012, Plow et al. 2011). Various 
self-management interventions have been developed for other conditions and 
symptoms such as HIV/AIDS (Nicholas et al. 2007), arthritis, diabetes, COPD and 
cancer-related fatigue and were proven effective (Barlow et al. 2002; Foster et al. 
2016). Bearing in mind the benefits of obtaining information from both clinicians and 
fellow patients/cancer survivors, a self-management educational intervention for CIPN 
co-designed by both patients/cancer survivors and clinicians, may be an effective 
approach (Robert et al. 2015).   
 
 
  
A few limitations of our study are worth noting. Although recruitment using social 
media was relatively easy, only those with access to such platforms were able to obtain 
information about study participation. Thus those interviewed were more likely to be 
technologically savvy individuals who obtain information via the internet. It is also 
possible that these participants were more likely to have severe CIPN, were persistently 
exploring CIPN information from various sources and therefore were more motivated 
to participate. Our recruitment approach may have excluded those with limited IT skills 
or limited means of finding information and, indeed, may have different experiences of 
getting CIPN information. Telephone interviews may also have affected participants’ 
responses. Some participants mentioned difficulty holding their phones for a long time 
due to existing CIPN symptoms, and they may have unconsciously limited their 
answers to shorten the interview. Most participants were diagnosed with ovarian 
cancer; all were Caucasian females, and over the age of fifty.  The researchers learned 
at a later stage of the recruitment that the study webpage was shared in an ovarian 
cancer support discussion forum bv a participant. This may explain the response 
received from ovarian cancer survivors. The experience of CIPN may be different for 
those with different cancer diagnoses, are male, younger s and individuals from ethnic 
minorities. The experience of CIPN among these populations should be explored in 
future research. 
 
 
While neurotoxic chemotherapy drugs remain a main treatment modality for treating 
cancer and as more and more individuals survive cancer, the incidence of CIPN among 
cancer survivors is likely to also increase. CIPN symptoms may linger years after 
chemotherapy treatment had finished. It is important to consider strategies to empower 
patients from the start of treatment to identify CIPN symptoms early, to proactively 
report their symptoms to clinicians and to effectively self-manage their symptoms. 
Research focused on developing interventions to address gaps in practice is essential to 
improve patient experience and to achieve as healthy and optimum patient quality of 
life as possible for patients who develop CIPN following treatment of cancer. 
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Table 1. Sample eligibility criteria  
 
 
Inclusion criteria Exclusion criteria 
 
Individuals who:  
 
• were diagnosed with ovarian, 
breast or colorectal cancer; 
• had experienced or are still 
experiencing symptoms of 
chemotherapy-induced peripheral 
neuropathy; 
• had received neurotoxic 
chemotherapy drugs for cancer 
treatment, 
• were 18 years old and above, 
• were willing to provide consent, 
• were UK-residents. 
 
 
Individuals who: 
 
• had peripheral neuropathy 
caused by other conditions such 
as diabetes or caused by cancer 
treatments other than 
chemotherapy; 
• were unable to speak and 
understand English due to lack 
of translation resources; 
• were unwilling to have their 
interviews recorded. 
 
  
Table 2. Participant profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID  Cancer diagnosis and 
stage 
Chemotherapy drugs Completed 
chemotherapy 
at the time of 
interview 
(Year and 
Month) 
Age Gender Ethnicity UK Region  Still experiencing 
CIPN symptoms 
01 Stage 3 ovary Paclitaxel and Carboplatin 2Y and 2M 60 Female White-British Devon Yes 
02 Stage 3c peritoneum 1st line: Paclitaxel and 
Carboplatin 
2nd line: Carboplatin then 
Cisplatin 
10Y 75 Female White-British Suffolk Yes 
03 Stage 1c ovary Carboplatin  2Y 58 Female  White-British Nottingham Yes 
04 Stage 2c ovary and 
right fallopian tube 
Paclitaxel and Carboplatin  2Y 74 Female White-British Cambridgeshire Yes 
05 Stage 2a ovary Paclitaxel and Carboplatin 18Y 76 Female White-British Glasgow Yes 
06 Stage 3c ovary Paclitaxel and Carboplatin 2Y and 6M 50 Female White - 
European 
Windsor  Yes 
07 Stage 3c ovary Paclitaxel and Carboplatin 1Y and 6M 51 Female White - 
European 
London Yes 
08 Ovary (stage unknown) Paclitaxel and Carboplatin 15Y 70 Female White - 
European 
London Yes 
09 Stage 2c ovary Paclitaxel and Carboplatin 1Y 51 Female White-British Hertfordshire Yes 
10 Stage 3c ovary Paclitaxel and Carboplatin 3Y 69 Female White-British Lincolnshire Yes 
11 Stage 1c ovary Paclitaxel and Carboplatin 5Y 54 Female White-British Staffordshire Yes 
12 Stage 2 breast  5FU, Epirubicin, 
Cyclophosphamide and Docetaxel 
9Y 53 Female White-British Cambridgeshire Yes 
13 Stage 3 ovary Paclitaxel and Carboplatin 5M 67 Female White-British Devon Yes 
14 Stage 3 ovary Paclitaxel and Carboplatin 2Y 69 Female White - 
European 
London Yes 
15 Stage 1c ovary  Paclitaxel and Carboplatin 9Y 54 Female White - 
European 
London Yes 
  
Table 3. Themes, subthemes and text examples of participant quotes  
 
Main themes Sub-themes Text examples 
The struggle to process CIPN 
information 
  
Overwhelming information before starting 
treatment 
“I think because you're so overwhelmed with the information about the fact that, one, that you've got cancer and  two, that you need to have chemotherapy treatment” (Participant 1)  
“I wasn’t in a position to think about side effects” (Participant 15)  
Little or no information about CIPN “I don't remember receiving any direct information from the nurses or anything.” (Participant 6)  
“There was a brief mention of the fact that sometimes carboplatin can cause pins and needles and a bit of numbness but this should wear off after treatment. And that's pretty much all that 
was there.   There was no warning that it could be a serious effect or that it could be long term.” (Participant 1)  
“I was probably given like an information sheet at the time… that was really it.” (Participant 12) 
Risk is uncertain “I told everybody.  I said, 'Look, this is bothering me now because it's still there.  My feet feel odd.'  And they just said, 'Oh yeah, that it is probably a bit of nerve damage.  Don't worry.  It 
will probably clear up,' and that was pretty much it. But it didn't and it got worse. (Participant 3)  
“I did speak to  the consultant who was my oncologist  but they just said that - I mean that was, you know, that was because of the treatment I was having and that they - well, both of the 
therapies did cause that and it may improve after I'd finished treatment.” (Participant 1)  
“I don’t know that I identified the neuropathy as, as being a particular concern because I think I’d been told repeatedly that it will improve, it will get better.” (Participant 9)  
“Well, I asked how long and, and quite rightly they would reply that everybody was individual and, you know, they couldn’t really say, but that it shouldn’t last for much beyond the ending 
of treatment.” (Participant 8) 
‘But   when you say, 'Well, I'm a bit worried about peripheral neuropathy,' 'Well, we don't think you'll get that.'    So you are dismissed.’ (Participant 4) 
Information and trust in 
clinicians are key  
 
Information  “I couldn’t feel anything at all. And that’s when he came and said to me, ‘I’m sorry, but we’re not prepared to give you your last one.’ And I think I burst into tears at that point because I was 
so excited this was my last one. And, this will kill anything that’s there…It took me a wee while to get my head round that. I  took charge of it so that I made the decisions.” (Participant 5)  
“I don’t think any of the information I was given  deterred me from going into chemo  to get the maximum benefit for myself  and then I just thought, ‘Well, I’ll cope with the side effects  
and when I’m not coping, I’ll chat to somebody and we’ll make a decision’” (Participant 10)  
“But I think maybe that sometimes they ought to give you the information because, at the end of the day, you're the one who's got to live with it afterwards.    I think they're so keen to get you 
to have the treatment because they know you need it to save your life they forget that … when they've saved your life you've got to live with the consequences of what they've done.  So I 
would rather have known.   I would still have probably had it.” (Participant 3)  
Trust  “I don't think it was my decision. It was the consultant, the oncologist. You know, I was happy to go along. Well, because I very much trusted what he was saying.” (Participant 2)  
“I’ve been asked for my opinion as has my husband as well, he was involved in all the consultations.  So I think because I had confidence in them, well not that you don’t question but you 
accept more I think.” (Participant 13) 
The experience of symptom-
reporting 
 
Reported but not followed-up  “I think that if you start noticing it halfway through chemotherapy there should be a point where you can discuss all of this.” (Participant 14) 
“I think as well there just needs to be some sort of assessment, I was never assessed after, I was never given any, it was only because I raised the subject, it was never mentioned during or 
after treatment, it was because I raised the subject later on after the treatment finished.” (Participant 11)  
“I reported it quite quickly, but it wasn’t followed up for several weeks, so I’d had then one more cycle of chemo before I had the opportunity to speak to my oncologist about it.” (Participant 
9) 
 Felt ignored “…it's just push the chemo, push the chemo and not thinking about the person.  And I think they have to think about the person. I think oncologists should listen more to their patients.” 
(Participant 5) 
“I think she should have picked up more when I raised my concerns.” (Participant 4)  
“It would have been nice to be - to have been taken seriously at the time. I think for cancer patients and certainly for those who suffer these different side  effects that are long lasting, if not 
permanent,  is being taken seriously.” (Participant 3)  
The challenges of  
managing symptoms 
 
Lack of practical advice on self-management “They always ask – so they track, for the purposes of the trial, the side effects. So I am always asked, without fail, about – about peripheral neuropathy, but no proactive information given, 
no.” (Participant 6) 
“And I think that's the sort of thing they should be looking at is 'What can we do when people have these effects, these side  effects?'  Whether they're permanent, long term, short term or 
whatever, we need somebody that can talk to them and explain to them what their options are, what they can do, how they can help. Advice on how to deal with it.” (Participant 3) 
“I didn’t realise there were things that might have helped.” (Participant 11) 
Patients actively looking for information  “You kind of have to accept that if there isn’t very much anyone can do for you that you’re a bit on your own.  That’s why you go to the forums, to find out if anyone has got a secret that 
helps them.” (Participant 14) 
“Just so really I went to places where I thought I could get help and advice and I've worked round it on that basis.” (Participant 6) 
Dealing with symptoms with minimal 
clinician input  
“You were just left to get on with it.” (Participant 6) 
 “No, there was no discussion about what can be done about it at all. It was very much it’s just one of the side-effects you might get. There was nothing about how you could ameliorate it or – 
nothing that I recall.” (Participant 7) 
“I didn't make a fuss so they weren't aware that I was suffering as much as I was” (Participant 1)  
  
Figure 1. Thematic map illustrating four main themes 
 
 
 
